Thromb Haemost 2022; 122(06): 1040-1046
DOI: 10.1055/s-0041-1736444
Atherosclerosis and Ischaemic Disease

Calcification Propensity in Serum and Cardiovascular Outcome in Peripheral Artery Disease

Marija Bojic
1   Division of Nephrology, Medicine III, Medical University of Vienna, Austria
,
Bernhard Bielesz
1   Division of Nephrology, Medicine III, Medical University of Vienna, Austria
,
Daniel Cejka
2   Department of Medicine III, Nephrology, Transplantation Medicine, Rheumatology, Geriatrics, Ordensklinikum Linz Elisabethinen, Linz, Austria
,
Gerit-Holger Schernthaner
3   Division of Angiology, Medicine II, Medical University of Vienna, Austria
,
3   Division of Angiology, Medicine II, Medical University of Vienna, Austria
› Author Affiliations
Funding The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: funding was provided by Medical University of Vienna, Vienna, Austria.

Abstract

Peripheral artery disease (PAD) has been shown to be linked to elevated cardiovascular risk. The novel T50 test quantifies calcification propensity of serum and has been associated with cardiovascular events and mortality in patients with chronic kidney disease (CKD) and in the general population. This study investigated the association of calcification propensity measured by the T50 test in 287 patients with PAD without severe CKD. Major cardiovascular events (MACEs) including nonfatal stroke and nonfatal myocardial infarction and all-cause death (MACE + ) were evaluated after a median follow-up of 4 years and long-term cardiovascular and all-cause mortality after a median follow-up of 8.7 years by Kaplan–Meier and Cox regression analyses. Mean T50 time was 268 ± 63 minutes in the study cohort (age 69 ± 10 years, 32% women, 47% diabetes). Low T50 values that signify high calcification propensity were significantly associated with the occurrence of MACE+ (hazard ratio [HR]: 0.72; 95% confidence interval [CI]: 0.55–0.94). This association sustained multivariate adjustment for cardiovascular risk factors (CVRFs), Fontaine PAD stage, and prevalent media sclerosis (HR: 0.65; CI: 0.47–0.91). Cardiovascular mortality was significantly associated with T50 after multivariate adjustment for CVRF (HR: 0.72; CI 0.53–0.99), but not all-cause mortality (HR: 0.80; CI: 0.64–1.01). In conclusion, calcification propensity associates with MACE+ and cardiovascular mortality in patients with PAD.

Author Contributions

All authors contributed to: (1) substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, and (3) final approval of the version to be published.


Supplementary Material



Publication History

Received: 13 May 2021

Accepted: 26 August 2021

Article published online:
31 October 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Bauer UE, Briss PA, Goodman RA, Bowman BA. Prevention of chronic disease in the 21st century: elimination of the leading preventable causes of premature death and disability in the USA. Lancet 2014; 384 (9937): 45-52
  • 2 Bauersachs R, Zeymer U, Brière JB, Marre C, Bowrin K, Huelsebeck M. Burden of coronary artery disease and peripheral artery disease: a literature review. Cardiovasc Ther 2019; 2019: 8295054
  • 3 Diehm C, Allenberg JR, Pittrow D. et al; German Epidemiological Trial on Ankle Brachial Index Study Group. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation 2009; 120 (21) 2053-2061
  • 4 O'Hare AM, Katz R, Shlipak MG, Cushman M, Newman AB. Mortality and cardiovascular risk across the ankle-arm index spectrum: results from the Cardiovascular Health Study. Circulation 2006; 113 (03) 388-393
  • 5 Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res 2015; 116 (09) 1509-1526
  • 6 Nancollas GH, LoRe M, Perez L, Richardson C, Zawacki SJ. Mineral phases of calcium phosphate. Anat Rec 1989; 224 (02) 234-241
  • 7 Naik V, Leaf EM, Hu JH. et al. Sources of cells that contribute to atherosclerotic intimal calcification: an in vivo genetic fate mapping study. Cardiovasc Res 2012; 94 (03) 545-554
  • 8 Heiss A, Jahnen-Dechent W, Endo H, Schwahn D. Structural dynamics of a colloidal protein-mineral complex bestowing on calcium phosphate a high solubility in biological fluids. Biointerphases 2007; 2 (01) 16-20
  • 9 Köppert S, Büscher A, Babler A. et al. Cellular clearance and biological activity of calciprotein particles depend on their maturation state and crystallinity. Front Immunol 2018; 9: 1991
  • 10 Aghagolzadeh P, Bachtler M, Bijarnia R. et al. Calcification of vascular smooth muscle cells is induced by secondary calciprotein particles and enhanced by tumor necrosis factor-α. Atherosclerosis 2016; 251: 404-414
  • 11 Pasch A, Jahnen-Dechent W, Smith ER. Phosphate, calcification in blood, and mineral stress: the physiologic blood mineral buffering system and its association with cardiovascular risk. Int J Nephrol 2018; 2018: 9182078
  • 12 Smith ER, Ford ML, Tomlinson LA. et al. Serum calcification propensity predicts all-cause mortality in predialysis CKD. J Am Soc Nephrol 2014; 25 (02) 339-348
  • 13 Keyzer CA, de Borst MH, van den Berg E. et al. Calcification propensity and survival among renal transplant recipients. J Am Soc Nephrol 2016; 27 (01) 239-248
  • 14 Dahle DO, Åsberg A, Hartmann A. et al. Serum calcification propensity is a strong and independent determinant of cardiac and all-cause mortality in kidney transplant recipients. Am J Transplant 2016; 16 (01) 204-212
  • 15 Pasch A, Block GA, Bachtler M. et al. Blood calcification propensity, cardiovascular events, and survival in patients receiving hemodialysis in the EVOLVE trial. Clin J Am Soc Nephrol 2017; 12 (02) 315-322
  • 16 Bundy JD, Cai X, Mehta RC. et al; CRIC Study Investigators. Serum calcification propensity and clinical events in CKD. Clin J Am Soc Nephrol 2019; 14 (11) 1562-1571
  • 17 Eelderink C, Te Velde-Keyzer CA, Frenay AS. et al; NIGRAM2+ consortium. Serum calcification propensity and the risk of cardiovascular and all-cause mortality in the general population: the PREVEND study. Arterioscler Thromb Vasc Biol 2020; 40 (08) 1942-1951
  • 18 Bundy JD, Cai X, Scialla JJ. et al; CRIC Study Investigators. Serum calcification propensity and coronary artery calcification among patients with CKD: the CRIC (Chronic Renal Insufficiency Cohort) study. Am J Kidney Dis 2019; 73 (06) 806-814
  • 19 Höbaus C, Herz CT, Obendorf F. et al. Center-based patient care enhances survival of elderly patients suffering from peripheral arterial disease. Ann Med 2017; 49 (04) 291-298
  • 20 Norgren L, Hiatt WR, Dormandy JA. et al; TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33 (Suppl. 01) S1-S75
  • 21 Mancia G, De Backer G, Dominiczak A. et al; The task force for the management of arterial hypertension of the European Society of Hypertension, The task force for the management of arterial hypertension of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28 (12) 1462-1536
  • 22 Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26 (Suppl. 01) S5-S20
  • 23 Levey AS, Stevens LA, Schmid CH. et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150 (09) 604-612
  • 24 Pasch A, Farese S, Gräber S. et al. Nanoparticle-based test measures overall propensity for calcification in serum. J Am Soc Nephrol 2012; 23 (10) 1744-1752
  • 25 Rothman KJ, Greenland S, Lash TL. Modern Epidemiology. 3rd ed.. Philadelphia, PA: Lippincott Williams & Wilkins; 2008: 258-282
  • 26 Nakatani S, Mori K, Sonoda M. et al. Association between serum zinc and calcification propensity (T50) in patients with type 2 diabetes mellitus and in vitro effect of exogenous zinc on T50 . Biomedicines 2020; 8 (09) 8
  • 27 Bielesz B, Reiter T, Marculescu R. et al. Calcification propensity of serum is independent of excretory renal function. Sci Rep 2017; 7 (01) 17941
  • 28 Bullen AL, Anderson CAM, Hooker ER. et al. Correlates of T50 and relationships with bone mineral density in community-living older men: the osteoporotic fractures in men (MrOS) study. Osteoporos Int 2019; 30 (07) 1529-1531
  • 29 Ridker PM, Everett BM, Thuren T. et al; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017; 377 (12) 1119-1131
  • 30 Kaptoge S, Seshasai SR, Gao P. et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J 2014; 35 (09) 578-589
  • 31 Smith ER, Hanssen E, McMahon LP, Holt SG. Fetuin-A-containing calciprotein particles reduce mineral stress in the macrophage. PLoS One 2013; 8 (04) e60904